Rocket Pharmaceuticals (RCKT) Expected to Announce Earnings on Monday

Key Points

• Rocket Pharmaceuticals is expected to report its Q2 2025 earnings on August 4th, with analysts projecting a loss of $0.57 per share and revenues of $4.36 million.
• The company recently reported a previous quarterly loss of $0.56 per share, beating analyst expectations, and is projected to have an average EPS of $-3 for the current fiscal year.
• Multiple investors, including AQR Capital Management and Goldman Sachs, have increased their holdings in Rocket Pharmaceuticals, showcasing growing institutional interest in the stock.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Monday, August 4th. Analysts expect Rocket Pharmaceuticals to post earnings of ($0.57) per share and revenue of $4.36 million for the quarter.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.02. During the same quarter in the prior year, the firm posted ($0.66) EPS. On average, analysts expect Rocket Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT stock traded down $0.06 during trading hours on Thursday, reaching $3.09. The company had a trading volume of 818,804 shares, compared to its average volume of 3,412,487. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.19 and a current ratio of 9.19. The business has a fifty day moving average price of $3.17 and a 200-day moving average price of $6.55. Rocket Pharmaceuticals has a one year low of $2.19 and a one year high of $24.74. The firm has a market cap of $329.43 million, a PE ratio of -1.17 and a beta of 0.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its holdings in Rocket Pharmaceuticals by 24.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 995,690 shares of the biotechnology company's stock valued at $6,641,000 after buying an additional 192,905 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Rocket Pharmaceuticals during the 1st quarter valued at approximately $189,000. Millennium Management LLC grew its holdings in shares of Rocket Pharmaceuticals by 121.8% in the first quarter. Millennium Management LLC now owns 747,147 shares of the biotechnology company's stock valued at $4,983,000 after purchasing an additional 410,238 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Rocket Pharmaceuticals by 148.4% in the first quarter. AQR Capital Management LLC now owns 163,622 shares of the biotechnology company's stock valued at $1,091,000 after purchasing an additional 97,758 shares in the last quarter. Institutional investors own 98.39% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on RCKT. Cantor Fitzgerald increased their price target on Rocket Pharmaceuticals from $20.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, May 16th. TD Cowen reaffirmed a "hold" rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, May 27th. Leerink Partners reaffirmed a "market perform" rating and set a $8.00 target price (down from $37.00) on shares of Rocket Pharmaceuticals in a report on Wednesday, May 28th. Chardan Capital reduced their price objective on Rocket Pharmaceuticals from $17.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, July 24th. Finally, Canaccord Genuity Group cut their price target on Rocket Pharmaceuticals from $11.00 to $10.00 and set a "buy" rating for the company in a report on Friday, July 25th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $17.87.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.